Evidence map›Paper›PMID 42269092›Full record

Observational studyEuropean heart journal. Cardiovascular pharmacotherapy2026

Longitudinal loop diuretic use in patients with HFrEF initiated with sodium-glucose cotransporter 2 inhibitors.

Daniela Tomasoni, Lina Benson, Javed Butler, Federica Guidetti, Michael Melin, Carin Corovic Cabrera, Marco Metra, Lars H Lund, Gianluigi Savarese

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniela TomasoniDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.
Lina BensonDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.ORCID 0000-0002-5393-0055
Javed ButlerBaylor Scott and White Research Institute, 3434 Live Oak St Ste 501, Dallas, TX 75204, USA.ORCID 0000-0001-7683-4720
Federica GuidettiDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.
Michael MelinDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.
Carin Corovic CabreraDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.
Marco MetraCardiology-ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25123 Brescia, Italy.
Lars H LundDepartment of Medicine, Division of Cardiology, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
Gianluigi SavareseDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm 118 83, Sweden.ORCID 0000-0001-7732-0887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsA reduction in loop diuretics need after sodium-glucose cotransporter-2 inhibitors (SGLT2i) initiation has been suggested by retrospective analyses of clinical trials. We aimed to investigate long-term changes in loop diuretic therapy after SGLT2i initiation in an unselected, real-world heart failure (HF) cohort. METHODS AND

resultsPatients with HF with reduced ejection fraction (HFrEF) enrolled in the SwedeHF between January 2020 and October 2021 were considered. Patients initiated with SGLT2i were the cases. Controls did not initiate SGLT2i despite having an indication. Trajectories in daily furosemide-equivalent doses from baseline to 1-year follow-up were compared in cases vs. controls. Overall, 5623 (81.6%) controls and 1265 (18.4%) cases were analysed. At baseline, 5224 (75.8%) patients were prescribed with loop diuretics with a mean (SD) furosemide-equivalent dose of 36.7 (27.4) mg. SGLT2i users, compared with controls, more likely experienced a loop diuretic withdrawal/dose reduction (difference between proportions 6% [3%; 9%] P-value <0.001), and less likely had a loop diuretic initiation or dose increase (difference between proportions -5% [-7%; -3%], P-value <0.001), leading to a more accentuated net decrease in furosemide-equivalent daily doses (adjusted mean difference between groups -4.2 [-7; -1.5] mg, P-value 0.002). In a multivariable regression model, the adjusted odds ratio (OR) for decrease in loop diuretic doses/withdrawn after SGLT2i initiation was 1.58 (1.35-1.85), and the adjusted OR for increase in loop diuretic doses/new initiation was 0.50 (0.38-0.64).

conclusionIn this real-world population with HFrEF, SGLT2i initiation was associated with a decrease in loop diuretic need at 1-year follow-up.

Indexed as

FurosemideHeart FailureSodium-Glucose Transporter 2 InhibitorsSodium Potassium Chloride Symporter InhibitorsStroke VolumeVentricular Function, LeftAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeFurosemideSodium-Glucose Transporter 2 InhibitorsSodium Potassium Chloride Symporter InhibitorsDoseFurosemideHFrEFLoop diureticsSGLT2 inhibitorsUse

Identifiers

PMID42269092
PMCPMC13588644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.